Dr. Katherine High Becomes President of American Society of Gene Therapy; Hematology Researcher at The Children's Hospital of Philadelphia Assumes Post in High-Profile Field of Medicine


PHILADELPHIA, June 2 /PRNewswire/ -- Katherine A. High, M.D., a leading
hematology researcher at The Children's Hospital of Philadelphia, began her term as president of the American Society of Gene Therapy (ASGT) at the Society's 7th Annual Meeting today in Minneapolis.

The ASGT is the largest medical professional organization representing
researchers and scientists dedicated to discovering new gene therapies. Gene
therapy, a very new field of medicine, holds the potential of treating human
disease at a fundamental level by delivering therapeutic genes directly into a patient's cells.

Dr. High is internationally prominent for her studies of the molecular biology of the inherited bleeding disorder, hemophilia. Over the past decade,
she has investigated a gene transfer approach to treating hemophilia B, the
second most common form of hemophilia, by delivering the gene to produce the blood clotting factor that is deficient in patients with the disease. During the ASGT meeting, Dr. High will report preliminary results of a clinical trial
of gene therapy for hemophilia B, conducted in a collaboration between The
Children's Hospital of Philadelphia and Stanford University.

In addition to her position at Children's Hospital, Dr. High is a Howard Hughes Medical Institute Investigator, one of 12 physician-scientists recently selected by the Institute for major accomplishments in patient-oriented research. She also is the William H. Bennett Professor of Pediatrics at the University of Pennsylvania School of Medicine.

Dr. High will serve as president of the ASGT until June 2005.

Founded in 1855 as the nation's first pediatric hospital, The Children's Hospital of Philadelphia is ranked today as the best pediatric hospital in the nation by U.S. News & World Report and Child magazine. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents from before birth through age 19. For more information, visit http://www.chop.edu.

John Ascenzi
The Children's Hospital of Philadelphia